Zhongzhi Pharmaceutical Holdings Temettü

Temettü kriter kontrolleri 0/6

Zhongzhi Pharmaceutical Holdings şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

0.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	0.3%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	HK$0.060
Ödeme oranı	0%

Son temettü güncellemeleri

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

May 05

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Apr 21

Recent updates

Little Excitement Around Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Earnings As Shares Take 26% Pounding

Aug 22

Calculating The Intrinsic Value Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)

Jun 19

Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation

May 10

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

May 05

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Apr 21

Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares

Feb 01

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

May 24

Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?

Aug 26

Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet

Apr 28

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Jun 11

Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)

May 06

Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues

Apr 21

Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?

Mar 29

The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More

Mar 05

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Feb 15

What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?

Jan 14

Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?

Dec 27

If You Like EPS Growth Then Check Out Zhongzhi Pharmaceutical Holdings (HKG:3737) Before It's Too Late

Dec 14

Did You Miss Zhongzhi Pharmaceutical Holdings' (HKG:3737) 31% Share Price Gain?

Nov 30

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 17

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 3737 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: 3737 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Zhongzhi Pharmaceutical Holdings Piyasaya Karşı Temettü Getirisi

3737 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (3737)	0%
Pazarın Alt %25'i (HK)	3.2%
Pazarın En İyi %25'i (HK)	7.9%
Sektör Ortalaması (Pharmaceuticals)	3.7%
Analist tahmini (3737) (3 yıla kadar)	n/a

Önemli Temettü: 3737 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 3737 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 3737 Hong Kong piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 3737 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Zhongzhi Pharmaceutical Holdings Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Zhongzhi Pharmaceutical Holdings Limited Approves the Declaration and Payment of Final Dividend

Upcoming dividend of HK$0.03 per share

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Zhongzhi Pharmaceutical Holdings Limited Approves Interim Dividend

Upcoming dividend of HK$0.06 per share at 8.8% yield

Recent updates

New minor risk - Market cap size

Zhongzhi Pharmaceutical Holdings Limited Announces Resignation of Peng Zhiyun as Non-Executive Director

New minor risk - Profit margin trend

First half 2024 earnings released: EPS: CN¥0.099 (vs CN¥0.16 in 1H 2023)

Little Excitement Around Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Earnings As Shares Take 26% Pounding

New minor risk - Market cap size

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 23, 2024

Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2024

Calculating The Intrinsic Value Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)

Now 20% undervalued after recent price drop

Zhongzhi Pharmaceutical Holdings Limited Approves the Declaration and Payment of Final Dividend

Upcoming dividend of HK$0.03 per share

Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Zhongzhi Pharmaceutical Holdings Limited, Annual General Meeting, May 17, 2024

Chairman recently bought HK$4.0m worth of stock

Full year 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.13 in FY 2022)

Final dividend of HK$0.03 announced

Zhongzhi Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Chairman recently bought HK$1.4m worth of stock

Zhongzhi Pharmaceutical Holdings Limited Approves Interim Dividend

Upcoming dividend of HK$0.06 per share at 8.8% yield

Chairman recently bought HK$467k worth of stock

First half 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.091 in 1H 2022)

Chairman recently bought HK$135k worth of stock

Chairman recently bought HK$955k worth of stock

First half 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.091 in 1H 2022)

Zhongzhi Pharmaceutical Holdings Limited Proposes Interim Dividend for the Six Months Ended 30 June 2023, Payable on 2 November 2023

Investor sentiment improves as stock rises 15%

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 23, 2023

Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Zhongzhi Pharmaceutical Holdings Limited Approves the Declaration and Payment of Special Dividend

Upcoming dividend of HK$0.09 per share at 5.4% yield

Full year 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.062 in FY 2021)

Zhongzhi Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Deputy GM & Executive Director recently bought HK$229k worth of stock

Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?

First half 2022 earnings released: EPS: CN¥0.091 (vs CN¥0.081 in 1H 2021)

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 25, 2022

Chairman recently bought HK$177k worth of stock

Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet

Chairman recently bought HK$448k worth of stock

Less than half of directors are independent

Zhongzhi Pharmaceutical Holdings Limited, Annual General Meeting, May 20, 2022

Investor sentiment improved over the past week

Chairman recently bought HK$925k worth of stock

Investor sentiment improved over the past week

Chairman recently bought HK$1.8m worth of stock

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2021

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.081 (vs CN¥0.086 in 1H 2020)

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)

Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.14 in FY 2019)

Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.14 in FY 2019)

Investor sentiment deteriorated over the past week

Zhongzhi Pharmaceutical Holdings Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

New 90-day high: HK$1.76